There are currently 34 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are Ohio, California, New York and Michigan.
Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCT04850495
Recruiting
This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-CHOP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunotherapy... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +1 locations
Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Register for Updates
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
NCT03656835
Recruiting
This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle [ILN] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse l... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Register for Updates
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
NCT06031194
Recruiting
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
Register for Updates
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017
Recruiting
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Innovative Clinical Research Institute ( Site 0122), Whittier, California +42 locations
Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Register for Updates
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
NCT05660395
Recruiting
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California +13 locations
Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Register for Updates
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL
NCT03960840
Recruiting
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University Of California LA UCLA Hematology Oncology, Los Angeles, California +40 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Register for Updates
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT03223610
Recruiting
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Register for Updates
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
NCT04981795
Recruiting
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Alabama Oncology, Birmingham, Alabama +23 locations
Conditions: Diffuse Large B-cell Lymphoma
Register for Updates
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
NCT04739813
Recruiting
Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas. Objective: To learn if it is safe and effectiv... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Register for Updates
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
NCT04002947
Recruiting
Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma
Register for Updates
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05451810
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: University of Arkansas for Medical Sciences /ID# 244562, Little Rock, Arkansas +52 locations
Conditions: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Register for Updates
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
NCT05660967
Recruiting
The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/03/2024
Locations: UW Cancer Center at ProHealth Care, Waukesha, Wisconsin +74 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates